Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the third quarter, Holdings Channel reports. The firm owned 1,298 shares of the biopharmaceutical company’s stock after purchasing an additional 19 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,365,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after buying an additional 91,956 shares during the period. Capital International Investors increased its position in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the period. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after acquiring an additional 59,769 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $782.51 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $780.95 and a twelve month high of $1,211.20. The business has a 50 day simple moving average of $1,000.06 and a 200-day simple moving average of $1,035.67. The company has a market capitalization of $85.99 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 3.10 and a beta of 0.15.

Analysts Set New Price Targets

A number of analysts recently weighed in on REGN shares. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $1,097.14.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.